PD-L1, IHC (Nivolumab)

Also known as: Opdivo®, Programmed Death Ligand 1

Clinical Use

Use

The PD-L1, IHC test is used to evaluate programmed cell death-ligand 1 (PD-L1) expression in tumor tissues. PD-L1 is an immune inhibitory receptor ligand expressed by tumor cells and tumor-associated immune cells. This test is particularly significant for patients undergoing treatment with nivolumab, as PD-L1 expression on tumor cells can help predict response to therapy in cases of non-small-cell lung cancer. This immunohistochemical evaluation aids in the selection of suitable candidates for immune checkpoint inhibitors, potentially improving treatment outcomes by identifying tumors that may respond to nivolumab treatment.

Special Instructions

Not provided.

Limitations

The PD-L1, IHC (Nivolumab) test is limited by the quality and quantity of the specimen. Insufficient tissue or inappropriate fixation may affect test results and interpretations. Additionally, this assay is validated specifically for formalin-fixed paraffin-embedded (FFPE) tissue blocks or slides and might not be suitable for other types of specimens. It is important to note the test is applicable mainly to non-small-cell lung cancer and may not be validated for other tumor types.

Test Details

Methodology

Immunoassay (IHC)

Biomarkers

PD-L1

Protein

% Tumor Cells Staining

Expression • Ordinal Score (e.g., TPS, CPS, H-score)

LOINC Codes

Order Codes

85148-5 - PD-L1 by 28-8 Tiss ImStn Doc

Result Codes

83054-7 - PD-L1 by 22C3 Tiss ImStn-Imp
83055-4 - PD-L1 by 28-8 Tiss Ql ImStn
83053-9 - Cells.PD-L1/Viab tum NFr Tiss ImStn
77202-0 - Laboratory comment Report
72486-4 - Lab director name Provider

Result Turnaround Time

5-9 days

Specimen

Tissue (FFPE)

Volume

One formalin-fixed paraffin-embedded (FFPE) tissue block or five unstained positively charged slides sectioned from FFPE tissue block at 4 to 5 microns.